BioSyent (CVE:RX) Shares Pass Below 50 Day Moving Average – Time to Sell?

BioSyent Inc. (CVE:RX) shares crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$11.29 and traded as low as C$10.96. BioSyent shares last traded at C$11.00, with a volume of 1,550 shares trading hands.

BioSyent Stock Performance

The firm has a market capitalization of C$127.49 million, a price-to-earnings ratio of 18.33 and a beta of 0.93. The company has a 50-day moving average price of C$11.29 and a 200-day moving average price of C$10.93. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19.

Insiders Place Their Bets

In other news, Senior Officer Robert Joseph March sold 4,775 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Also, insider FAX Capital Corp. sold 112,400 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of C$11.28, for a total transaction of C$1,267,557.28. In the last three months, insiders have sold 349,144 shares of company stock worth $3,903,370. 33.65% of the stock is owned by corporate insiders.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.